The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
at c3 mins in to the video Richard emphasises a very positive note that those who had been using steroids still got the positive impact, isn't that massive news!
I appreciate your courteous and thought through reply @Starjump.
I don't have a reason to doubt any of the upsides presented in that presentation and i wouldn't have objected so much if they had provided the same level of detail that you gave as one possible use of the funding. They essentially got paid £316k per word of their use of proceeds statement and it galled me.
As you say though, all down to your risk appetite, belief and research into the stock.
I get everyone's optimism and wish for the company to thrive but that is a borderline offensive lack of detail as to why they needed £6m
It's flying! Quickly up 13% maybe Smokey bought in...
Apologies if its been shared before but came across a recent IHS Markit report about an analysis of US H1 car buying patterns. Some of the key segments which had shown most resilience were in pick-up trucks and the luxury segments with the greatest decline being in economy / compact cars. This bodes well as an early indicator that the Covid impact on our key partners like Ford and Mercedes will not be as bad as other market areas.
Full report here - https://cdn.ihsmarkit.com/www/pdf/0820/2020-08-17-H1-US-Auto-Market-Analysis-IHS-Markit.pdf
The past few weeks have helped solidify in my mind how the overall market is shaping out into segments and we are squarely in the high capability / premium segment which will likely have lower overall volume than some other providers but it will be significantly easier to protect price and margins as the market grows.
Recent events with the RNS/Pillar strategy have also reminded me of a notorious story from back in the hey days of WWF and WCW wrestling where one promotion owner attempted to laud it over another that they were the king of the wrestling business when the other one turns round and congratulates him while letting him know that he's actually in the sports entertainment business now. Just seemed to ring parallels with the recent RNS's from two companies which i'm sure you could guess at.
Personally I'm ****ed off that it's a potentially unlimited dilution which individual investors are locked out of given with no warning without any real rationale contrary to indications given in very recent communications from the company.
I feel like this guy in the launch haha, give me a massage and play me some jazz :)
A couple more thoughts.... please excuse if i've gotten too rampy...
(1) could we see a post launch RNS today giving further detail on the contract scope, duration and perhaps revenues? Maybe the often derided SEE RNS machine is now fixed and working through a backlog of announcements?
(2) We've always heard about this being a 'Jam tomorrow' type stock, and i can't even start to empathise with the people who've held for 10+ years but if we're nearing 'Jam day' then this could become huge in a hurry, we can start talking about the fair market values? Simply Wall Street has us as 97.1% undervalued with a fair value of £1.04, that would be some climb!
Revisionist history right there. Irrespective of anything SNG related they have blood on their hands.
Feels like this is the beginning of the SEE endgame, was hoping i had a few more weeks to move some cash in (awaiting a transfer into my SIPP) but the timing of this with the big launch today, the cash stability and hard baked profits from auto indicate to me that this could be a real catalyst for the next leg of our journey.
They probably saw an opportunity with Oxford Biomedica and then thought better of it
https://vm.tiktok.com/ZMJBgeRo7/
Ironically found on tiktok but it does raise a good question as to how do you even start to run this tiktok business without the people and the experience
Matt Hanc ock did say that the government were supporting further trials back in July
So what i don't get is why dexamethasone was fast tracked into use after successful signals in the trial where it only seemed to improve the outcomes of 1 in 8 people.
Using the same logic why would you not continue to use a therapeutic which helped the outcomes of 4 in 5 people as in SNG001?
So my theory which i'd like someone knowledgeable to disprove, is that after the data results came in, hospitals have continued to use SNG001 and the added numbers reported on the trials site reflect how many people have been part of these upgraded 'Pivotal' phase 2 trials and they are only waiting on the at home groups before they can do a full assessment of results.
To aid this, the 'administrative' update to the trials site added a whole bunch of new criteria which would open up the home trial to the over 50's group including 'BMI over 30, high temperature, loss of smell and/or taste' which should rapidly increase takeup.
Someone shoot me down.
From the Company’s inception the principle of offering a freight service with company owned vehicles has remained.
Hi-Trans Express firmly believes in owning its own fleet.
We know that fleet ownership offers us the kind of control over fleet movements, driver training and vehicle maintenance that is not possible with a fully subcontracted fleet, as employed by many of our competitors.
Today, Hi-Trans Express owns over 200 late-model units. This includes over 50 prime movers (with an average age of only 5 years) and in excess of 150 trailers.
https://www.hi-trans.com.au/services/
'The data still needs to be peer-reviewed and we are supporting a further large scale trial, but these preliminary results are a positive sign.'
This indicates it might already have happened, been paid for and could have completed surely as that was on 20th July. Maybe the vastly reduced recent death rate was due to SNG001?
On the basis that this is going ahead for a vastly expanded P3/Pivotal stage trial, who paid for it? Understanding on here is that these things are very expensive so without any notification of a placing or fund raising, how did that happen?
IMHO - Very positive!
The eligibility criteria seems to have been expanded in the home setting as well
'Male or female, =18 years of age (hospital setting) or =50 years of age (home setting) at the time of consent.'
The updated estimated enrollment figure submitted on 25th August says 820 against an initial estimated enrollment of 400, could that indicate that it has been continuously used since the original trial?
Is this newly confirmed information JoeyD?
Synairgen has conducted randomised placebo controlled clinical trials of SNG001 involving >200 asthma and COPD patients. These trials have shown that SNG001 has:
been well tolerated during virus infections
enhanced antiviral activity in the lungs (measured in sputum and blood samples)
provided significant lung function benefit over placebo in asthma in two Phase II trials.
Synairgen believes SNG001 could help prevent worsening or accelerate recovery of severe lower respiratory tract illness in COVID-19 patients.